We serve Chemical Name:4-chlorobutoxymethylbenzene CAS:125340-68-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-chlorobutoxymethylbenzene
CAS.NO:125340-68-3
Synonyms:Benzene,[(4-chlorobutoxy)methyl];4-BENZYLOXY-1-CHLOROBUTANE;1-(BENZYLOXY)-4-CHLOROBUTANE;(2S,3S)-4-benzyloxy-2,3-epoxybutyl chloride
Molecular Formula:C11H15ClO
Molecular Weight:198.68900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:9.23000
Exact Mass:198.08100
LogP:3.22220
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzene,[(4-chlorobutoxy)methyl] chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2S,3S)-4-benzyloxy-2,3-epoxybutyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-BENZYLOXY-1-CHLOROBUTANE Use and application,4-BENZYLOXY-1-CHLOROBUTANE technical grade,usp/ep/jp grade.
Related News: What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. 4-chlorobutoxymethylbenzene manufacturer CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion. 4-chlorobutoxymethylbenzene supplier CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion. 4-chlorobutoxymethylbenzene vendor What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. 4-chlorobutoxymethylbenzene factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.
